Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science research tools, analytical instruments, and diagnostics, has announced a significant restructuring of its brand architecture — one designed to make it easier for scientists and clinicians to identify and access the solutions they need based on their application and stage of research. The new structure organizes Bio-Techne’s expansive portfolio under three focused portfolio brands, each aligned with a distinct phase of the scientific journey: from early discovery through translational research to clinical diagnostics.
The announcement was made on April 16, 2026, and the newly aligned portfolio will make its public debut at two major scientific meetings: the American Association for Cancer Research (AACR) Annual Meeting in San Diego and IMMUNOLOGY2026™ in Boston.
Why Bio-Techne Is Reorganizing Its Portfolio
Bio-Techne has spent five decades building one of the most comprehensive and scientifically rigorous portfolios in the life sciences industry — spanning high-quality recombinant proteins, antibodies, immunoassays, small molecules, protein analytical instruments, spatial biology platforms, and clinical diagnostic reagents. Over that time, the company has grown through both internal development and strategic acquisitions, assembling a collection of industry-leading brands that serve researchers and clinicians across virtually every stage of scientific inquiry.
The breadth of that portfolio, while a scientific strength, has also created a navigational challenge for customers. With dozens of product lines, brand names, and technology platforms operating under the Bio-Techne umbrella, identifying the right solution for a specific application or research stage required familiarity with the full scope of the company’s offerings — not always straightforward for scientists focused on the demands of their own research programs.
The new brand architecture addresses this directly. By organizing the portfolio into three clearly defined brands — each corresponding to a recognizable phase of the research and clinical workflow — Bio-Techne makes its solutions more accessible to the customers who need them, regardless of their prior familiarity with the company’s full range of offerings.
Kim Kelderman, President and Chief Executive Officer of Bio-Techne, articulated the rationale behind the restructuring:
“At Bio-Techne, our focus is empowering scientists and clinicians to achieve better answers that lead to more breakthroughs. By aligning our portfolio with the fast-paced progression of scientific research, we make it easier for customers to access the solutions they need to advance their work and accelerate scientific progress.”
Kelderman also emphasized the strategic significance of the change beyond customer experience: “Our updated brand structure strengthens our position as a trusted scientific partner, bringing greater alignment across our expanding portfolio and reinforcing our mission to improve the quality of life by catalyzing advances in science and medicine.”
The Three Portfolio Brands
R&D Systems™: Empowering Better Answers in Scientific Discovery
The R&D Systems portfolio serves as the starting point of the scientific journey — the foundation of tools that researchers rely on to explore, experiment, and generate the biological insights that precede translational and clinical work.
Under the new architecture, R&D Systems brings together Bio-Techne’s trusted proteins, antibodies, immunoassays, small molecules, and innovative analytical instruments. These are the reagents and tools that scientists worldwide depend on to generate reproducible results, validate discoveries, and advance early-stage research toward clinical application with confidence.
R&D Systems also encompasses key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows — reflecting the increasing importance of regulated-quality research materials in the development of next-generation therapeutics.
The R&D Systems brand now consolidates several legacy Bio-Techne brands under a single identity, including Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™ — each of which has an established reputation within specific research communities and application areas.
Bio-Techne Spatial™: Empowering Better Answers in Translational Research
The Bio-Techne Spatial portfolio occupies the middle stage of the scientific journey — the translational research phase where biological findings from early discovery are placed in tissue and disease context, and where their relevance to clinical questions is evaluated.
Bio-Techne Spatial leverages the company’s industry-leading spatial biology technologies to enable scalable, high-resolution visualization of RNA and protein expression directly within intact tissue sections. The portfolio is anchored by two complementary platforms: the gold-standard RNAscope™ in situ hybridization technology, which enables single-molecule RNA detection at single-cell resolution in clinical and research specimens; and the automated COMET™ spatial hyperplex platform, which enables high-plex RNA and protein co-detection for comprehensive multiomics profiling of tissue architecture.
Together, these platforms deliver exceptional sensitivity and precision for applications including biomarker discovery and validation, tumor microenvironment characterization, cell therapy tissue analysis, and pathology-driven research in clinical specimens. Bio-Techne Spatial solutions are used across academic research, pharmaceutical and biotechnology drug development, and translational medicine programs that require spatially resolved, tissue-level molecular data to support their scientific and regulatory goals.
The Bio-Techne Spatial brand consolidates the legacy brands Lunaphore™ and Advanced Cell Diagnostics™ — the original developer of RNAscope™ technology — under a unified identity that reflects the full scope of the spatial biology portfolio.
Bio-Techne Diagnostics™: Empowering Better Answers in Diagnostics
The Bio-Techne Diagnostics portfolio represents the clinical end of the scientific journey — the application of molecular and biochemical science to clinical decision-making, patient diagnosis, and laboratory quality assurance.
Bio-Techne Diagnostics provides clinical laboratories and in vitro diagnostic (IVD) manufacturers with the assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the complete lifecycle of assay development — from early design and analytical validation through deployment at scale in clinical laboratory settings.
By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure the accuracy and reliability that clinical diagnostic workflows require — ultimately contributing to improved patient outcomes through better-informed clinical decisions.
The Bio-Techne Diagnostics brand brings together several established legacy brands: Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls — each representing a specialized area of clinical diagnostic supply and assay development support.
A Connected Path from Discovery to the Clinic
The three portfolio brands are designed not as isolated business units but as an interconnected continuum — a deliberate representation of how modern science actually progresses. A biological target discovered using R&D Systems reagents may be subsequently characterized in tissue context using Bio-Techne Spatial platforms, and ultimately measured in clinical samples using Bio-Techne Diagnostics assay materials. The new brand structure makes that progression explicit, signaling to customers that Bio-Techne’s solutions are designed to support the full arc of scientific and clinical work rather than discrete, disconnected stages.
This end-to-end alignment is increasingly important in a research and clinical landscape where the boundaries between discovery science, translational research, and clinical diagnostics are becoming more fluid — particularly in fields like oncology, cell and gene therapy, and precision medicine, where the translation of research findings into clinical tools is both faster and more direct than it has historically been.
Fifty Years of Scientific Partnership
The brand restructuring comes as Bio-Techne celebrates 50 years of operation — a milestone that reflects both the longevity of the company’s scientific contributions and the depth of trust it has built with the research and clinical communities it serves. Over five decades, Bio-Techne has grown from a regional provider of biochemical reagents into a global life sciences company with operations in 34 locations worldwide, approximately 3,100 employees, and over $1.2 billion in net sales in fiscal year 2025.
The company’s portfolio of more than 500,000 products is used by academic researchers, biopharmaceutical and biotechnology companies, and clinical diagnostic laboratories around the world — a scale of reach that reflects both the breadth of Bio-Techne’s scientific offerings and the trust those communities place in the quality and reliability of its products.
The new brand architecture is designed to make that trust more navigable — ensuring that whether a scientist is beginning a target discovery program, a translational researcher is characterizing a biomarker in patient tissue, or a clinical laboratory director is sourcing materials for an IVD assay development project, they can quickly identify which part of Bio-Techne’s portfolio is most relevant to their needs.
Debut at AACR 2026 and IMMUNOLOGY2026™
The newly aligned portfolio brands will make their public debut at two of the most prominent scientific meetings in the life sciences calendar. R&D Systems and Bio-Techne Spatial will be represented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego — one of the world’s largest cancer research conferences — and at AAI’s IMMUNOLOGY2026™ in Boston, a premier forum for immunology research and translational immunology.
Both meetings offer Bio-Techne the opportunity to present its newly organized portfolio to the scientific communities whose work most directly benefits from its discovery, spatial, and diagnostic solutions — and to demonstrate in a conference setting how the three brands connect to form an integrated scientific resource.
For more information about Bio-Techne and its brands, visit www.bio-techne.com.